Literature DB >> 7527603

Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.

B Charreau1, A Cassard, L Tesson, B Le Mauff, J M Navenot, D Blanchard, D Lublin, J P Soulillou, I Anegon.   

Abstract

The present study analyzed the ability of human decay-accelerating factor (DAF) and CD59 to protect rat endothelial cell (EC) clones from human and primate complement-mediated lysis. By flow cytometry and Scatchard analysis, we show that human DAF and/or CD59 cDNAs under the transcriptional control of elongation factor 1-alpha promoter were expressed at levels similar to or higher than that of a human EC line. Human DAF and CD59 were released from the surface of transfected rat cells by phosphatidylinositol phospholipase C, demonstrating that the two molecules were linked to the cell membrane by means of a glycolipid anchor. The functional activity of the two human C regulatory proteins expressed on rat EC lines was studied using an in vitro assay of C-dependent cytotoxic in which rat EC were incubated with human or nonhuman primate sera as sources of xenogeneic natural antibodies and C. We demonstrate that human and monkey xenogeneic natural antibodies bind to rat cells and induce lysis by a C-dependent mechanism involving mainly the C direct activation pathway. Our data indicate that human DAF and CD59, expressed either alone or in combination, abrogated all EC cytotoxicity, even in the presence of 50% human serum. This protective phenotype was correlated with decreased membrane attack complex (CD59 and/or DAF transfectants) and C3 deposition (DAF transfectants) on EC surface. Antibodies against the transfected molecules abolished the protection against C-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527603

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

1.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates.

Authors:  B Charreau; S Ménoret; L Tesson; A Azimzadeh; M Audet; P Wolf; R Marquet; C Verbakel; J Ijzermans; P Cowan; M Pearse; A d'Apice; J P Soulillou; I Anegon
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

3.  Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.

Authors:  C L Harris; O B Spiller; B P Morgan
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

4.  Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.

Authors:  C L Harris; A S Williams; S M Linton; B P Morgan
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

5.  Loxosceles spider venom induces metalloproteinase mediated cleavage of MCP/CD46 and MHCI and induces protection against C-mediated lysis.

Authors:  Carmen W Van Den Berg; Rute M Gonçalves De Andrade; Fabio C Magnoli; Kevin J Marchbank; Denise V Tambourgi
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

6.  Analysis of human CD59 tissue expression directed by the CMV-IE-1 promoter in transgenic rats.

Authors:  B Charreau; L Tesson; J Buscail; J P Soulillou; I Anegon
Journal:  Transgenic Res       Date:  1996-11       Impact factor: 2.788

7.  An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice.

Authors:  Marieta M Ruseva; Valeria Ramaglia; B Paul Morgan; Claire L Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

8.  Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.

Authors:  Saema Magre; Yasuhiro Takeuchi; Gillian Langford; Andrew Richards; Clive Patience; Robin Weiss
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

Authors:  Christoph Q Schmidt; Markus J Harder; Eva-Maria Nichols; Mario Hebecker; Markus Anliker; Britta Höchsmann; Thomas Simmet; Ádám I Csincsi; Barbara Uzonyi; Isabel Y Pappworth; Daniel Ricklin; John D Lambris; Hubert Schrezenmeier; Mihály Józsi; Kevin J Marchbank
Journal:  Immunobiology       Date:  2016-01-06       Impact factor: 3.144

10.  Human decay-accelerating factor and CEACAM receptor-mediated internalization and intracellular lifestyle of Afa/Dr diffusely adhering Escherichia coli in epithelial cells.

Authors:  Julie Guignot; Sylvie Hudault; Imad Kansau; Ingrid Chau; Alain L Servin
Journal:  Infect Immun       Date:  2008-11-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.